Ultrasound-guided perineal laser ablation versus prostatic arterial embolization for benign prostatic hyperplasia: two similar short-term efficacies.

Background: There are many ways to treat prostatic hyperplasia; these are currently more inclined to minimally invasive treatment. We mainly compared the differences between two treatment methods， ultrasound-guided transperineal laser ablation (US-TPLA) and prostatic artery embolization (PAE).

Purpose: To evaluate the efficacy and safety of US-TPLA and PAE in the treatment of benign prostatic hyperplasia (BPH).

Material And Methods: The clinical information for 40 patients with BPH admitted to our hospital between June 2018 and January 2021 were retrospectively analyzed. The changes in International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), postvoid residual (PVR), prostate volume (PV), and the incidence of complications were compared between groups.

Results: The IPSS ( < 0.001;  < 0.001), QoL ( < 0.001;  < 0.001), Qmax ( < 0.001;  < 0.001), PVR ( < 0.001;  < 0.001), and PV ( < 0.001;  < 0.001) at three and six months after US-TPLA and PAE improved with respect to those before surgery. There was no significant difference in IPSS ( = 0.235;  = 0.151), QoL ( = 0.527;  = 0.294), Qmax ( = 0.776;  = 0.420), PVR ( = 0.745;  = 0.607), and PV ( = 0.527;  = 0.573) between the groups at three and six months after surgery. No serious complications occurred in either group.

Conclusion: US-TPLA and PAE seem to have a similar short-term efficacy. The efficacy of the two procedures is comparable, and neither is associated with serious complications. US-TPLA and PAE are both effective complementary measures for the treatment of BPH.